New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
The cardiology community is increasingly questioning the value of adding on a variety of lipid therapies to treatment with highly effective statins, based on accumulating evidence of the lack of value of affecting cholesterol parameters other than LDL.
You may also be interested in...
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
If the aspirin/omeprazole finally gets approved on its third FDA review, Aralez then will face the challenge of positioning a prescription product against generic, over-the counter versions of both of its main components.
Surrogate markers for cardiovascular products may be going the way of AbbVie's cholesterol franchise.